Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development 英文参考文献.docVIP

Pharmaceuticals 2010, 3, 2821-2837; doi:10.3390/ph3092821 OPEN ACCESS pharmaceuticals ISSN 1424-8247 /journal/pharmaceuticals Review Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development Janet Wangari-Talbot 1,2,3, James Goydos 1,2 and Suzie Chen 3,* 1 Graduate School of Biomedical Sciences-Robert Wood Johnson Medical School, Piscataway, 08854 New Jersey, USA 2 Department of Surgery, Cancer Institute of New Jersey, New Brunswick, 08901 New Jersey, USA 3 Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, 08854-8020 New Jersey, USA * Author to whom correspondence should be addressed; E-Mail: suziec@; Tel.: 732-445-3400 x 227; Fax: 732-445-0687. Received: 2 July 2010; in revised form: 18 August 2010 / Accepted: 20 August 2010 / Published: 26 August 2010 Abstract: Melanoma remains one of the cancers for which a decline in morbidity has not been achieved with current scientific and medical advances. Mono-therapies targeting melanoma have been largely ineffective, increasing the need for identification of new drugable targets. Multiple tumor suppressors and oncogenes that impart genetic predisposition to melanoma have been identified and are being studied in an attempt to provide insight on the development of anti-melanoma therapies. Metabotropic Glutamate Receptor I (GRM1) has recently been implicated as a novel oncogene involved in melanomagenesis. GRM1 (mGlu1, protein) belongs to the G protein coupled receptor (GPCR) super family and is normally functional in the central nervous system. Our group showed in a transgenic mouse model system that ectopic expression of Grm1 in melanocytes is sufficient to induce spontaneous melanoma development in vivo. GPCRs are some of the most important therapeutic drug targets discovered to date and they make up